Research-centric peptide and protocol reference hub
### Summary Sermorelin is a synthetic peptide that mimics growth hormone-releasing hormone (GHRH), stimulating the pituitary gland to produce and release endogenous growth hormone. It has been investigated for its potential therapeutic applications, particularly in the context of growth hormone deficiencies and other related conditions.
Aggregate AI baseline blended with community voting. Hover to inspect effect strengths per category.
Effect scores blend an AI baseline with community votes. Open the full chart to see sliders and vote on each category.
Compact view of how logs describe shifts in pain, sleep, and performance (−5 to +5). Treat this as qualitative, anonymous signal only.
No community research logs yet. When structured logs are added, this panel will summarize typical shifts in pain, sleep, and performance.
Rough heatmap of anonymous side-effect and positive-signal tags — a "most-mentioned" snapshot, not safety or efficacy advice.
No anonymous side-effect reports yet. When reports are submitted, this panel will show a simple heatmap of tags like "nausea", "flushing", "improved healing", and more.
Studies, clinical trials, community discussions, and news.
This study evaluated the effects of Tesamorelin therapy on body composition and adipose tissue in individuals with HIV lipodystrophy. The specific dosage and duration of therapy were not reported in the abstract. The findings indicate changes in body composition metrics, but no therapeutic claims are made.
This study investigated the effects of GHRH (Sermorelin) on cognition in aging individuals and those with mild cognitive impairment (MCI). The specific dose and duration of treatment were not reported in the abstract. The outcomes measured were cognitive function and related assessments.
This study assessed cardiovascular risk markers in growth hormone (GH) deficient patients with nonsecreting pituitary adenomas. The specific dose of Sermorelin administered is not reported in the abstract. The outcomes measured were various cardiovascular risk markers, but specific results are not detailed.
This study investigated the relationship between growth hormone deficiency, empty sella, and cardio-metabolic risk factors in individuals with obesity. The specific doses of sermorelin administered were not detailed in the abstract. The findings suggest associations but do not establish causation.
This study investigated the effects of GHRH (Sermorelin) on sleep promotion and endocrine regulation in service members with traumatic brain injury and insomnia. The specific dose and duration were not reported in the abstract. The outcomes measured included various sleep and endocrine parameters.
This study investigated the effects of short-term growth hormone administration in HIV-infected patients. The specific dose and duration of treatment were not reported in the abstract. The outcomes measured were not detailed in the abstract.
This study assessed the efficacy and long-term safety of a 2 mg dose of TH9507, a GHRH analog, in HIV subjects with excess abdominal fat accumulation. The study was multicenter, double-blind, and randomized, comparing TH9507 to placebo. Specific outcomes were not reported in the abstract.
This study evaluated the variability of growth hormone (GH) and insulin-like growth factor I (IGF-I) measurements across different assays. The analysis included participants receiving Sermorelin, although specific details about the population and dosing were not provided. The findings highlight the importance of assay variability in interpreting GH and IGF-I levels.
Not reported in abstract.
Not reported in abstract.
Not reported in abstract.
Helpful external resources for additional structural, pharmacologic, and literature context. These are third-party databases; always cross-check details with primary research.
No comments yet. Share research notes, citations, or observations below.
No community research logs yet. Use the “Contribute data” button above to share an anonymized summary of your experience.
This section describes how anonymous side-effect reports are aggregated into the heatmap above. Reports are anonymous and unverified, and should be read alongside primary safety data.
Use the "Report side effects" button to open a focused popup form. Please keep descriptions neutral and avoid medical language; think in terms of "nausea", "flushing", "vivid dreams", etc.
Every time the Librarian touches this peptide — discovering, refreshing, scoring, or verifying — it logs the action here.
Scored effects for Sermorelin
Refreshed content for Sermorelin
Refreshed content for Sermorelin
Refreshed content for Sermorelin
Refreshed content for Sermorelin
Refreshed content for Sermorelin
Scored effects for Sermorelin
Verified content for Sermorelin: accurate
Completed task: Find real articles for Sermorelin (thin literature)
Searched for real articles on Sermorelin
Refreshed content for Sermorelin
Auto-summarized study: "Growth hormone - releasing hormone antagonists induce autophagy in cancer cells...."
Auto-summarized study: "Growth Hormone-Releasing Hormone Antagonists Increase Radiosensitivity in Non-Sm..."
Auto-summarized study: "Semantic Scholar search for Sermorelin..."
Refreshed content for Sermorelin
Refreshed content for Sermorelin
Refreshed content for Sermorelin